Security record · archived quarter
HAE
Haemonetics Corporation · Healthcare · Medical - Devices
14Tracked holders
0Δ holders
9.30MShares held
$726.05MReported value
+1New positions
−1Exits
Momentum inputs (comparable managers): holder breadth 0.0% · share flow -5.2% · net new positions 0.0% — formula
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q4 2024
Ownership over time
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 106 | -6 | 39.46M | $2.63B | +3 | −9 |
| Q1 2026 | 115 | +1 | 38.93M | $1.98B | +9 | −9 |
| Q4 2025 | 115 | -1 | 49.79M | $3.32B | +2 | −2 |
| Q3 2025 | 19 | 0 | 21.92M | $1.07B | +1 | −2 |
| Q2 2025 | 17 | +1 | 20.74M | $1.55B | +1 | — |
| Q1 2025 | 13 | -1 | 9.03M | $573.92M | +1 | −2 |
| Q4 2024 | 14 | 0 | 9.30M | $726.05M | +1 | −1 |
| Q3 2024 | 13 | -3 | 7.86M | $631.67M | — | −3 |
| Q2 2024 | 16 | — | 7.65M | $633.10M | — | — |
Who holds it · Q4 2024
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Wellington Management ✦ | 3.94M | -6.2% | $307.65M | 0.1% | ▼ Trim | 3 | SEC ↗ |
| 2 | Wellington Management ✦ | 3.94M | -6.2% | $307.65M | 0.1% | ▼ Trim | 3 | SEC ↗ |
| 3 | Wellington Management ✦ | 3.94M | -6.2% | $307.65M | 0.1% | ▼ Trim | 3 | SEC ↗ |
| 4 | Wellington Management ✦ | 3.94M | -6.2% | $307.65M | 0.1% | ▼ Trim | 3 | SEC ↗ |
| 5 | Wellington Management ✦ | 3.94M | -6.2% | $307.65M | 0.1% | ▼ Trim | 3 | SEC ↗ |
| 6 | State Street Global Advisors ✦ (passive) | 1.95M | — | $152.02M | 0.0% | n/c | 1 | SEC ↗ |
| 7 | State Street Global Advisors ✦ (passive) | 1.95M | — | $152.02M | 0.0% | n/c | 1 | SEC ↗ |
| 8 | Geode Capital Management ✦ (passive) | 1.18M | -1.1% | $92.24M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 9 | Geode Capital Management ✦ (passive) | 1.18M | -1.1% | $92.24M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 10 | Fisher Asset Management ✦ | 711.77K | +3.2% | $55.58M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 11 | Norges Bank ✦ (passive) | 420.12K | -14.0% | $32.80M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 12 | T. Rowe Price ✦ | 354.28K | +7.8% | $27.66M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 13 | T. Rowe Price ✦ | 354.28K | +7.8% | $27.66M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 14 | Marshall Wace ✦ | 280.00K | +25.6% | $21.86M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 15 | Marshall Wace ✦ | 280.00K | +25.6% | $21.86M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 16 | Marshall Wace ✦ | 280.00K | +25.6% | $21.86M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 17 | Citadel Advisors ✦ | 189.44K | -44.5% | $14.79M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 18 | Citadel Advisors ✦ | 189.44K | -44.5% | $14.79M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 19 | Millennium Management ✦ | 162.31K | -33.9% | $12.67M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 20 | Two Sigma Investments ✦ | 58.80K | -24.1% | $4.59M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 21 | AQR Capital Management ✦ | 25.24K | +80.3% | $1.95M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 22 | AQR Capital Management ✦ | 25.24K | +80.3% | $1.95M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 23 | AQR Capital Management ✦ | 25.24K | +80.3% | $1.95M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 24 | D. E. Shaw & Co. ✦ | 18.24K | New | $1.42M | 0.0% | New | 1 | SEC ↗ |
| 25 | Bridgewater Associates ✦ | 5.39K | -31.1% | $421,007 | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 26 | Gotham Asset Management ✦ | 4.91K | 0.0% | $383,685 | 0.0% | Held | 3 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| D. E. Shaw & Co. | $1.42M | 0.0% |
Exited
| Renaissance Technologies | $3.38M | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 321 holders, 47.04M shares, $2.56B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
Frequently co-owned
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Provenance: Ownership from parsed 13F common-stock positions (tracked universe, comparable sets for changes); insider rows from Forms 3/4/5; stakes from Schedules 13D/13G; every filing links to its original on SEC EDGAR.
Reporting period: Q4 2024 ·
Methodology ·
Get this via the API